Masahiro Kurobe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Masahiro Kurobe has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
- Naoki Yoshimura
University of Pittsburgh School of Medicine
9 shared publications - Ei‐Ichiro Takaoka
Department of Urology University of Pittsburgh School of Medicine Pittsburgh Pennsylvania USA
4 shared publications Takahisa Suzuki
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
4 shared publicationsHiroyuki Nishiyama
Department of Urology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
3 shared publicationsNobutaka Shimizu
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
3 shared publicationsShinsuke Mizoguchi
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
3 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by Wiley in Neurourology and Urodynamics
Functional Roles of Adenosine A 2B and A 3 Receptor Subtypes in the Bladder of Male Rats With A 2B Receptor Deletion or Bladder Outlet Obstruction
Purpose: To investigate the adenosine receptor (AR) mechanism underlying bladder outlet obstruction (BOO)‐related bladder dysfunction, we examined the expression level of AR subtypes in bladder tissues, and the effects of AR subtypes A2B & A3 modulation on bladder activity using male BOO rats, and Dahl rats with A2B receptor deletion. Materials and Methods: BOO was induced by partial ligation of the proximal urethra in male Sprague‐Dawley rats. At 4 weeks after BOO, conscious cystometrograms (CMG) were performed with the urethral ligature being intact. The effects of AR A3 agonist (2CL‐IB‐MECA) and AR A3 antagonist (MRS3777) were examined by intravesical administration. Furthermore, we examined the difference of bladder function of AR subtypes between AR A2B knockout (A2B‐KO) and wild‐type groups of male Dahl rats. mRNA levels of AR subtypes in bladder tissues were also analyzed. Results: BOO versus sham rats showed heavier bladder weights, higher contraction amplitudes, and increased numbers of non‐voiding contractions (NVCs) during the filling phase. In the bladder mucosa – but not the detrusor ‐ of BOO versus sham rats, mRNA expression levels of A2A and A3 AR were significantly increased, while A2B levels were significantly decreased. In BOO rats, an A3 antagonist (MRS 3777; 10 and 100 μM) had no effect on CMG parameters. However, a high dose of an A3 agonist (2CL‐IB‐MECA; 100 μM) significantly increased NVCs ( p = 0.0034), an effect that was blocked by the A3 antagonist. Additionally, compared to wild‐type rats, A2B‐KO rats showed a significant increase in the number of NVCs ( p = 0.0039). Conclusions: A2B AR down‐regulation in BOO rats and A2B deletion in Dahl rats could contribute to the development of bladder overactivity. Moreover, a high‐level of exogenous activation of A3 ARs might exacerbate bladder overactivity in BOO.
- 31 August 2026
- Published by Wiley in Neurourology and Urodynamics
Open AccessFunctional Roles of Adenosine A 2B and A 3 Receptor Subtypes in the Bladder of Male Rats With A 2B Receptor Deletion or Bladder Outlet Obstruction
Purpose: To investigate the adenosine receptor (AR) mechanism underlying bladder outlet obstruction (BOO)‐related bladder dysfunction, we examined the expression level of AR subtypes in bladder tissues, and the effects of AR subtypes A2B & A3 modulation on bladder activity using male BOO rats, and Dahl rats with A2B receptor deletion. Materials and Methods: BOO was induced by partial ligation of the proximal urethra in male Sprague‐Dawley rats. At 4 weeks after BOO, conscious cystometrograms (CMG) were performed with the urethral ligature being intact. The effects of AR A3 agonist (2CL‐IB‐MECA) and AR A3 antagonist (MRS3777) were examined by intravesical administration. Furthermore, we examined the difference of bladder function of AR subtypes between AR A2B knockout (A2B‐KO) and wild‐type groups of male Dahl rats. mRNA levels of AR subtypes in bladder tissues were also analyzed. Results: BOO versus sham rats showed heavier bladder weights, higher contraction amplitudes, and increased numbers of non‐voiding contractions (NVCs) during the filling phase. In the bladder mucosa – but not the detrusor ‐ of BOO versus sham rats, mRNA expression levels of A2A and A3 AR were significantly increased, while A2B levels were significantly decreased. In BOO rats, an A3 antagonist (MRS 3777; 10 and 100 μM) had no effect on CMG parameters. However, a high dose of an A3 agonist (2CL‐IB‐MECA; 100 μM) significantly increased NVCs ( p = 0.0034), an effect that was blocked by the A3 antagonist. Additionally, compared to wild‐type rats, A2B‐KO rats showed a significant increase in the number of NVCs ( p = 0.0039). Conclusions: A2B AR down‐regulation in BOO rats and A2B deletion in Dahl rats could contribute to the development of bladder overactivity. Moreover, a high‐level of exogenous activation of A3 ARs might exacerbate bladder overactivity in BOO.
- Open Access
- 18 March 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (6) , 759
Back Muscle Strength Is Associated with Self-Reported Morning-Erection Frequency in Apparently Healthy Japanese Male University Students: A Cross-Sectional Study
Background/Objectives: Morning erections provide an intercourse-independent indicator of nocturnal erectile physiology. We aimed to examine whether body mass index (BMI) and muscle strength are associated with morning-erection frequency in apparently healthy Japanese male university students. Methods: This cross-sectional study analyzed 125 men with complete data (170 assessed; 45 excluded). Handgrip and back muscle strength were measured using dynamometry; BMI was calculated from height and weight. Morning-erection frequency was assessed using a single 6-category item and was dichotomized as low vs. high. Univariable and multivariable logistic regression models were fitted. Exploratory principal component analysis (PCA) and k-means clustering (k = 2, silhouette-supported) were performed. Results: Seventy-four participants (59.2%) were classified as low frequency. Back muscle strength was associated with high frequency (univariable odds ratio [OR] 1.61; 95% confidence interval [CI] 1.07–2.42; and p = 0.021) and remained significant after adjustment for BMI and handgrip strength (OR 1.88; 95% CI 1.02–3.47; and p = 0.045), whereas BMI and handgrip strength were not significant. Clustering identified two clusters (n = 41 and n = 84); Cluster 2 (higher BMI/strength) had a higher proportion of high morning-erection frequency (48% vs. 27%). Conclusions: In apparently healthy young men, greater back muscle strength was independently associated with higher self-reported morning-erection frequency. In this cohort, 59.2% reported infrequent morning erections, suggesting potential relevance even in early adulthood. Given the exploratory clustering, the single-item outcome, and likely residual confounding, these findings are hypothesis-generating and warrant longitudinal validation.
- 18 March 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (6) , 759
Open AccessBack Muscle Strength Is Associated with Self-Reported Morning-Erection Frequency in Apparently Healthy Japanese Male University Students: A Cross-Sectional Study
Background/Objectives: Morning erections provide an intercourse-independent indicator of nocturnal erectile physiology. We aimed to examine whether body mass index (BMI) and muscle strength are associated with morning-erection frequency in apparently healthy Japanese male university students. Methods: This cross-sectional study analyzed 125 men with complete data (170 assessed; 45 excluded). Handgrip and back muscle strength were measured using dynamometry; BMI was calculated from height and weight. Morning-erection frequency was assessed using a single 6-category item and was dichotomized as low vs. high. Univariable and multivariable logistic regression models were fitted. Exploratory principal component analysis (PCA) and k-means clustering (k = 2, silhouette-supported) were performed. Results: Seventy-four participants (59.2%) were classified as low frequency. Back muscle strength was associated with high frequency (univariable odds ratio [OR] 1.61; 95% confidence interval [CI] 1.07–2.42; and p = 0.021) and remained significant after adjustment for BMI and handgrip strength (OR 1.88; 95% CI 1.02–3.47; and p = 0.045), whereas BMI and handgrip strength were not significant. Clustering identified two clusters (n = 41 and n = 84); Cluster 2 (higher BMI/strength) had a higher proportion of high morning-erection frequency (48% vs. 27%). Conclusions: In apparently healthy young men, greater back muscle strength was independently associated with higher self-reported morning-erection frequency. In this cohort, 59.2% reported infrequent morning erections, suggesting potential relevance even in early adulthood. Given the exploratory clustering, the single-item outcome, and likely residual confounding, these findings are hypothesis-generating and warrant longitudinal validation.
- Open Access
- 1 January 2026
- Published by XMLink in Investigative and Clinical Urology
- Vol. 67 (2) , 178-185
Near infrared ray-guided partial cystectomy using da Vinci Firefly ® technology and intraoperative cystoscopy for urachal cyst, suspected of urachal tumor
Kurobe M, et al. Investig Clin Urol. 2026 Feb;67:e16. https://doi.org/10.4111/icu.20250141
- 1 January 2026
- Published by XMLink in Investigative and Clinical Urology
- Vol. 67 (2) , 178-185
Open AccessNear infrared ray-guided partial cystectomy using da Vinci Firefly ® technology and intraoperative cystoscopy for urachal cyst, suspected of urachal tumor
Kurobe M, et al. Investig Clin Urol. 2026 Feb;67:e16. https://doi.org/10.4111/icu.20250141
- Open Access
- 30 June 2022
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 134, 105337
A constrained mixture-micturition-growth (CMMG) model of the urinary bladder: Application to partial bladder outlet obstruction (BOO)
- 30 June 2022
- Published by Elsevier in Journal of the Mechanical Behavior of Biomedical Materials
- Vol. 134, 105337
Open AccessA constrained mixture-micturition-growth (CMMG) model of the urinary bladder: Application to partial bladder outlet obstruction (BOO)
- 1 May 2020
- Published by Elsevier in Life Sciences
- Vol. 249, 117537
Urethral dysfunction and alterations of nitric oxide mechanisms in streptozotocin-induced diabetic rats with or without low-dose insulin treatment
- 1 May 2020
- Published by Elsevier in Life Sciences
- Vol. 249, 117537
Urethral dysfunction and alterations of nitric oxide mechanisms in streptozotocin-induced diabetic rats with or without low-dose insulin treatment
- 20 March 2020
- Published by Wiley in BJU International
- Vol. 125 (6) , 911-919
Effects of a selective androgen receptor modulator (SARM), GSK2849466A, on stress urinary incontinence and bladder activity in rats with ovariectomy‐induced oestrogen deficiency
Objectives: To report the effect of a selective androgen receptor modulators (SARMs) on the urethral continence mechanisms in a rat model of stress urinary incontinence (SUI) induced by bilateral ovariectomy (OVX). Materials and methods: Female Sprague‐Dawley rats with bilateral OVX were used. Rats were divided into five groups; sham operated, vehicle‐treated OVX, low‐dose SARM‐treated OVX (GSK2849466A: 0.005 mg/kg/day, per os [p.o.]), high‐dose SARM‐treated OVX (GSK2849466A: 0.03 mg/kg/day, p.o.) and dihydrotestosterone (DHT)‐treated OVX (1 mg/kg/day, subcutaneous) groups. After 4 weeks of SARM treatments or 3 weeks of DHT treatment (6 weeks after OVX), rats were subjected to evaluation of the sneeze‐induced continence reflex using microtransducer‐tipped catheter methods, sneeze‐induced leak‐point pressure, and continuous cystometry measurements, followed by histological analyses of urethral tissues. Results: (i) OVX significantly impaired urethral continence function after 6 weeks to induce SUI during sneezing. (ii) Low‐dose SARM treatment restored urethral baseline pressure (UBP) without affecting the amplitude of urethral response during sneezing (A‐URS), partially reversing OVX‐induced SUI during sneezing. (iii) High‐dose SARM treatment reversed decreases in both UBP and A‐URS, more effectively preventing SUI during sneezing. (iv) DHT treatment only restored A‐URS without affecting UBP, partially preventing OVX‐induced SUI during sneezing. (v) The high‐dose SARM treatment induced hypertrophy of the striated and smooth muscle around the urethra. (vi) SARM treatment did not affect bladder function in sham or OVX rats. Conclusion: Treatment with SARMs could be a more effective modality for the treatment of SUI than DHT, without affecting bladder function, by enhancing smooth‐ and striated muscle‐mediated urethral function under stress conditions such as sneezing.
- 20 March 2020
- Published by Wiley in BJU International
- Vol. 125 (6) , 911-919
Effects of a selective androgen receptor modulator (SARM), GSK2849466A, on stress urinary incontinence and bladder activity in rats with ovariectomy‐induced oestrogen deficiency
Objectives: To report the effect of a selective androgen receptor modulators (SARMs) on the urethral continence mechanisms in a rat model of stress urinary incontinence (SUI) induced by bilateral ovariectomy (OVX). Materials and methods: Female Sprague‐Dawley rats with bilateral OVX were used. Rats were divided into five groups; sham operated, vehicle‐treated OVX, low‐dose SARM‐treated OVX (GSK2849466A: 0.005 mg/kg/day, per os [p.o.]), high‐dose SARM‐treated OVX (GSK2849466A: 0.03 mg/kg/day, p.o.) and dihydrotestosterone (DHT)‐treated OVX (1 mg/kg/day, subcutaneous) groups. After 4 weeks of SARM treatments or 3 weeks of DHT treatment (6 weeks after OVX), rats were subjected to evaluation of the sneeze‐induced continence reflex using microtransducer‐tipped catheter methods, sneeze‐induced leak‐point pressure, and continuous cystometry measurements, followed by histological analyses of urethral tissues. Results: (i) OVX significantly impaired urethral continence function after 6 weeks to induce SUI during sneezing. (ii) Low‐dose SARM treatment restored urethral baseline pressure (UBP) without affecting the amplitude of urethral response during sneezing (A‐URS), partially reversing OVX‐induced SUI during sneezing. (iii) High‐dose SARM treatment reversed decreases in both UBP and A‐URS, more effectively preventing SUI during sneezing. (iv) DHT treatment only restored A‐URS without affecting UBP, partially preventing OVX‐induced SUI during sneezing. (v) The high‐dose SARM treatment induced hypertrophy of the striated and smooth muscle around the urethra. (vi) SARM treatment did not affect bladder function in sham or OVX rats. Conclusion: Treatment with SARMs could be a more effective modality for the treatment of SUI than DHT, without affecting bladder function, by enhancing smooth‐ and striated muscle‐mediated urethral function under stress conditions such as sneezing.
- 1 March 2020
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 318 (3) , F754-F762
Urethral dysfunction in a rat model of chemically induced prostatic inflammation: potential involvement of the MRP5 pump
Prostate inflammation (PI) is a clinical condition associated with infection and/or inflammation of the prostate. It is a common disease frequently associated to lower urinary tract (LUT) symptoms. The urethra is an understudied structure in the LUT and plays a fundamental role in the urinary cycle. Here, we proposed to evaluate the effect of PI on the urethra tissue. Male Sprague-Dawley rats were used, and PI was induced by formalin injection into the ventral lobes of the prostate. The pelvic urethra at the prostatic level was harvested for histological analysis, contraction (electrical field stimulation and phenylephrine), and relaxation (sodium nitroprusside/MK-571) experiments. Various gene targets [cytochrome c oxidase subunit 2, transforming growth factor-β1, interleukin-1β, hypoxia-inducible factor-1α, α1A-adrenoceptor, inositol 1,4,5-trisphosphate receptor type 1, voltage-gated Ca2+ channel subunit-α1D, neuronal nitric oxide synthase, soluble guanylyl cyclase, phosphodiesterase 5A, protein kinase CGMP-dependent 1, and multidrug resistance-associated protein 5 (MRP5; ATP-binding cassette subfamily C member 5)] were quantified, and cGMP levels were measured. No histological changes were detected, and functional assays revealed decreased contraction and increased relaxation of urethras from the PI group. The addition of MK-571 to functional assays increased urethral relaxation. Genes associated with inflammation were upregulated in urethras from the PI group, such as cytochrome oxidase c subunit 2, transforming growth factor-β1, interleukin-1β, and hypoxia-inducible factor-1α. We also found increased expression of L-type Ca2+ channels and the neuronal nitric oxide synthase enzyme and decreased expression of the MRP5 pump. Finally, cGMP production was enhanced in urethral tissue of PI animals. The results indicate that PI is associated with proinflammatory gene expression in the urethra without histologically evident inflammation and that PI produces a dysfunctional urethra and MRP5 pump downregulation, which results in cGMP accumulation inside the cell. These findings would help to better understand LUT dysfunctions associated with PI and the role of MRP pumps in the control of LUT function.
- 1 March 2020
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 318 (3) , F754-F762
Urethral dysfunction in a rat model of chemically induced prostatic inflammation: potential involvement of the MRP5 pump
Prostate inflammation (PI) is a clinical condition associated with infection and/or inflammation of the prostate. It is a common disease frequently associated to lower urinary tract (LUT) symptoms. The urethra is an understudied structure in the LUT and plays a fundamental role in the urinary cycle. Here, we proposed to evaluate the effect of PI on the urethra tissue. Male Sprague-Dawley rats were used, and PI was induced by formalin injection into the ventral lobes of the prostate. The pelvic urethra at the prostatic level was harvested for histological analysis, contraction (electrical field stimulation and phenylephrine), and relaxation (sodium nitroprusside/MK-571) experiments. Various gene targets [cytochrome c oxidase subunit 2, transforming growth factor-β1, interleukin-1β, hypoxia-inducible factor-1α, α1A-adrenoceptor, inositol 1,4,5-trisphosphate receptor type 1, voltage-gated Ca2+ channel subunit-α1D, neuronal nitric oxide synthase, soluble guanylyl cyclase, phosphodiesterase 5A, protein kinase CGMP-dependent 1, and multidrug resistance-associated protein 5 (MRP5; ATP-binding cassette subfamily C member 5)] were quantified, and cGMP levels were measured. No histological changes were detected, and functional assays revealed decreased contraction and increased relaxation of urethras from the PI group. The addition of MK-571 to functional assays increased urethral relaxation. Genes associated with inflammation were upregulated in urethras from the PI group, such as cytochrome oxidase c subunit 2, transforming growth factor-β1, interleukin-1β, and hypoxia-inducible factor-1α. We also found increased expression of L-type Ca2+ channels and the neuronal nitric oxide synthase enzyme and decreased expression of the MRP5 pump. Finally, cGMP production was enhanced in urethral tissue of PI animals. The results indicate that PI is associated with proinflammatory gene expression in the urethra without histologically evident inflammation and that PI produces a dysfunctional urethra and MRP5 pump downregulation, which results in cGMP accumulation inside the cell. These findings would help to better understand LUT dysfunctions associated with PI and the role of MRP pumps in the control of LUT function.
- 10 February 2020
- Published by Wiley in Neurourology and Urodynamics
- Vol. 39 (3) , 916-925
Urethral dysfunction and therapeutic effects of a PDE 5 inhibitor (tadalafil) in a rat model of detrusor underactivity induced by pelvic nerve crush injury
Aims: The urethral dysfunction produced by a rat model of peripheral neurogenic detrusor underactivity (DU) using pelvic nerve crush (PNC) injury was characterized and then tested with the administration of tadalafil, a phosphodiesterase type 5 (PDE 5) inhibitor.Methods: Ten days after producing PNC rats, awake cystometrograms (CMGs) and isovolumetric cystometrograms with urethral perfusion pressure (IC‐UPP) measurements were performed. Also, in control rats, IC‐UPP was recorded before and after intravenous atropine administration to determine if the reduction of bladder contraction pressure affects urethral relaxation during voiding. Then, CMG and IC‐UPP measurements in PNC rats were recorded after intravenous administration of tadalafil. Lastly, real‐time polymerase chain reaction was used to measure transcript levels of neuronal nitric oxide synthases (nNOS), endothelial nitric oxide synthases, and PDE 5 in urethral specimens from PNC and control rats.Results: PNC rats demonstrated the characteristics of DU in CMG. Also, PNC rats exhibited significant decreases in isovolumetric bladder contraction amplitudes and urethral relaxation. Atropine attenuated the amplitude of isovolumetric bladder contractions; however, atropine did not affect urethral relaxation in control rats. Tadalafil decreased postvoid residual and increased voiding efficiency without changing bladder contraction amplitude in PNC rats. Also, tadalafil improved the amplitude of urethral relaxation during bladder contraction in PNC rats. Urethral nNOS transcript levels were upregulated in PNC rats compared to control rats.Conclusions: PNC rats revealed both DU and impaired urethral relaxation. PDE 5 inhibition in PNC rats enhanced urethral relaxation during voiding, resulting in improved voiding efficiency. Thus, urethral dysfunction could be a potential target for the treatment of inefficient voiding associated with neurogenic DU.
- 10 February 2020
- Published by Wiley in Neurourology and Urodynamics
- Vol. 39 (3) , 916-925
Urethral dysfunction and therapeutic effects of a PDE 5 inhibitor (tadalafil) in a rat model of detrusor underactivity induced by pelvic nerve crush injury
Aims: The urethral dysfunction produced by a rat model of peripheral neurogenic detrusor underactivity (DU) using pelvic nerve crush (PNC) injury was characterized and then tested with the administration of tadalafil, a phosphodiesterase type 5 (PDE 5) inhibitor.Methods: Ten days after producing PNC rats, awake cystometrograms (CMGs) and isovolumetric cystometrograms with urethral perfusion pressure (IC‐UPP) measurements were performed. Also, in control rats, IC‐UPP was recorded before and after intravenous atropine administration to determine if the reduction of bladder contraction pressure affects urethral relaxation during voiding. Then, CMG and IC‐UPP measurements in PNC rats were recorded after intravenous administration of tadalafil. Lastly, real‐time polymerase chain reaction was used to measure transcript levels of neuronal nitric oxide synthases (nNOS), endothelial nitric oxide synthases, and PDE 5 in urethral specimens from PNC and control rats.Results: PNC rats demonstrated the characteristics of DU in CMG. Also, PNC rats exhibited significant decreases in isovolumetric bladder contraction amplitudes and urethral relaxation. Atropine attenuated the amplitude of isovolumetric bladder contractions; however, atropine did not affect urethral relaxation in control rats. Tadalafil decreased postvoid residual and increased voiding efficiency without changing bladder contraction amplitude in PNC rats. Also, tadalafil improved the amplitude of urethral relaxation during bladder contraction in PNC rats. Urethral nNOS transcript levels were upregulated in PNC rats compared to control rats.Conclusions: PNC rats revealed both DU and impaired urethral relaxation. PDE 5 inhibition in PNC rats enhanced urethral relaxation during voiding, resulting in improved voiding efficiency. Thus, urethral dysfunction could be a potential target for the treatment of inefficient voiding associated with neurogenic DU.
- 1 November 2019
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 317 (5) , F1305-F1310
Therapeutic effects of inhibition of brain-derived neurotrophic factor on voiding dysfunction in mice with spinal cord injury
We investigated the involvement of brain-derived neurotrophic factor (BDNF) in bladder and urethral dysfunction using spinal cord-injured mice. We evaluated bladder and urethral function of female mice with 4-wk spinal cord injury (SCI) by filling cystometry and electromyography (EMG) of the external urethral sphincter (EUS) under a conscious condition. Anti-BDNF antibodies (10 μg·kg−1·h−1) were administered in some mice for 1 wk before the evaluation. Bladder and spinal (L6−S1) BDNF protein levels were examined by ELISA. Transcript levels of transient receptor potential channels or acid-sensing ion channels (Asic) in L6−S1 dorsal root ganglia were evaluated by RT-PCR. Voided volume and voiding efficiency were significantly increased without any changes in nonvoiding contractions, and the duration of reduced EMG activity during the voiding phase was significantly prolonged in anti-BDNF antibody-treated SCI mice. Compared with spinal cord-intact mice, SCI mice showed increased concentrations of bladder and spinal BDNF. Anti-BDNF antibody treatment decreased bladder and spinal BDNF protein concentrations of SCI mice. Asic2 and Asic3 transcripts were significantly increased after SCI but decreased after anti-BDNF antibody administration. These results indicate that upregulated expression of bladder and spinal BDNF is involved in the emergence of inefficient voiding in SCI mice. Thus, BDNF-targeting treatment could be an effective modality for the treatment of voiding problems, including inefficient voiding and detrusor sphincter dyssynergia after SCI.
- 1 November 2019
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 317 (5) , F1305-F1310
Therapeutic effects of inhibition of brain-derived neurotrophic factor on voiding dysfunction in mice with spinal cord injury
We investigated the involvement of brain-derived neurotrophic factor (BDNF) in bladder and urethral dysfunction using spinal cord-injured mice. We evaluated bladder and urethral function of female mice with 4-wk spinal cord injury (SCI) by filling cystometry and electromyography (EMG) of the external urethral sphincter (EUS) under a conscious condition. Anti-BDNF antibodies (10 μg·kg−1·h−1) were administered in some mice for 1 wk before the evaluation. Bladder and spinal (L6−S1) BDNF protein levels were examined by ELISA. Transcript levels of transient receptor potential channels or acid-sensing ion channels (Asic) in L6−S1 dorsal root ganglia were evaluated by RT-PCR. Voided volume and voiding efficiency were significantly increased without any changes in nonvoiding contractions, and the duration of reduced EMG activity during the voiding phase was significantly prolonged in anti-BDNF antibody-treated SCI mice. Compared with spinal cord-intact mice, SCI mice showed increased concentrations of bladder and spinal BDNF. Anti-BDNF antibody treatment decreased bladder and spinal BDNF protein concentrations of SCI mice. Asic2 and Asic3 transcripts were significantly increased after SCI but decreased after anti-BDNF antibody administration. These results indicate that upregulated expression of bladder and spinal BDNF is involved in the emergence of inefficient voiding in SCI mice. Thus, BDNF-targeting treatment could be an effective modality for the treatment of voiding problems, including inefficient voiding and detrusor sphincter dyssynergia after SCI.
- 3 October 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 39 (1) , 108-115
Role of p38 MAP kinase signaling pathways in storage and voiding dysfunction in mice with spinal cord injury
Aim: To investigate the role of p38 MAP kinase in lower urinary tract dysfunction in mice with spinal cord injury (SCI).Methods: Cystometry and external urethral sphincter‐electromyography were performed under an awake condition in 4‐week SCI female mice. Two weeks after SCI, a catheter connected to an osmotic pump filled with a p38 mitogen‐activated protein kinase (MAPK) inhibitor or artificial cerebrospinal fluid (CSF) was implanted into the intrathecal space of L6‐S1 spinal cord for continuous intrathecal instillation at infusion rate of 0.51 μL/h for 2 weeks before the urodynamic study. L6 dorsal root ganglia were then removed from CSF and p38 MAPK inhibitor‐treated SCI mice as well as from CSF‐treated normal (spinal intact) mice to evaluate the levels of transient receptor potential cation channel subfamily V member 1 (TRPV1), tumor necrosis factor‐α (TNF‐α), and inducible nitric oxide synthase (iNOS) transcripts by real‐time polymerase chain reaction.Results: In p38 MAPK inhibitor‐treated SCI mice, nonvoiding contractions during bladder filling, bladder capacity, and post‐void residual volume were significantly reduced while micturition pressure and voiding efficiency were significantly increased in comparison to these measurements in CSF‐treated SCI mice. The expression of TRPV1, TNF‐α, and iNOS messenger RNA was increased in SCI mice compared with expression in spinal intact mice and significantly decreased after p38 MAPK inhibitor treatment.Conclusions: The p38 MAPK signaling pathway in bladder sensory neurons or in the spinal cord plays an important role in storage and voiding problems such as detrusor overactivity and inefficient voiding after SCI.
- 3 October 2019
- Published by Wiley in Neurourology and Urodynamics
- Vol. 39 (1) , 108-115
Role of p38 MAP kinase signaling pathways in storage and voiding dysfunction in mice with spinal cord injury
Aim: To investigate the role of p38 MAP kinase in lower urinary tract dysfunction in mice with spinal cord injury (SCI).Methods: Cystometry and external urethral sphincter‐electromyography were performed under an awake condition in 4‐week SCI female mice. Two weeks after SCI, a catheter connected to an osmotic pump filled with a p38 mitogen‐activated protein kinase (MAPK) inhibitor or artificial cerebrospinal fluid (CSF) was implanted into the intrathecal space of L6‐S1 spinal cord for continuous intrathecal instillation at infusion rate of 0.51 μL/h for 2 weeks before the urodynamic study. L6 dorsal root ganglia were then removed from CSF and p38 MAPK inhibitor‐treated SCI mice as well as from CSF‐treated normal (spinal intact) mice to evaluate the levels of transient receptor potential cation channel subfamily V member 1 (TRPV1), tumor necrosis factor‐α (TNF‐α), and inducible nitric oxide synthase (iNOS) transcripts by real‐time polymerase chain reaction.Results: In p38 MAPK inhibitor‐treated SCI mice, nonvoiding contractions during bladder filling, bladder capacity, and post‐void residual volume were significantly reduced while micturition pressure and voiding efficiency were significantly increased in comparison to these measurements in CSF‐treated SCI mice. The expression of TRPV1, TNF‐α, and iNOS messenger RNA was increased in SCI mice compared with expression in spinal intact mice and significantly decreased after p38 MAPK inhibitor treatment.Conclusions: The p38 MAPK signaling pathway in bladder sensory neurons or in the spinal cord plays an important role in storage and voiding problems such as detrusor overactivity and inefficient voiding after SCI.